X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

By Stephen J. Ubl  |    January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...   Read More

ICER glosses over significant progress in MS treatment

By Holly Campbell  |    November 30, 2016
Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the...   Read More

ICYMI: More than 60 PhRMA company scientists visit Capitol Hill

By Andrew Powaleny  |    September 30, 2016
Last week, PhRMA brought more than 60 member company researchers and scientists to Capitol Hill for a biopharmaceutical researcher fly-in. The fly-in highlighted the important science that’s...   Read More

ICYMI: Multi-stakeholder group recommended changes to support value-driven health care

By Michelle Drozd  |    September 14, 2016
As part of PhRMA’s efforts to explore policy solutions to promote value-driven health care, we recently participated in a forum convened by Deloitte and the Network for Excellence in Health...   Read More

Making drug formulary search tools better for patients

By Rebecca Davison  |    September 7, 2016
There is a real need for patients to have information about out-of-pocket costs and clinical tools being used when it comes to their coverage. A new prescription drug search tool that includes...   Read More

ICER puts hard-fought progress in non-small cell lung cancer treatment at risk

By Holly Campbell  |    September 1, 2016
Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell...   Read More

Improving FDA’s combination product review process could increase epinephrine auto-injector competition

By Stephen J. Ubl  |    August 30, 2016
Combination products that consist of a medicine and delivery device are important treatment options for patients and have the potential to improve public health. Innovator companies invest in...   Read More

Empowering consumers and improving access to important clinical information

By Allyson Funk  |    August 29, 2016
Even though more Americans are insured than ever before, many are facing insurance barriers that may interfere with a doctor’s prescribed course of treatment and impact their care. We recently...   Read More

340B Spotlight: Retail pharmacies continue to expand the 340B program

By Rebecca Davison  |    August 17, 2016
One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels  found more than one-in-four retail, mail and specialty pharmacies in...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates